Trials / Completed
CompletedNCT00862992
Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia
Phase II Study of MP-214 in Patients With Schizophrenia (Exploratory Study)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of 3 fixed doses of MP-214 orally administered once daily to patients with schizophrenia. MP-214 tablets will be administered to patients starting at an initial dose, followed by up-titration to a fixed dose (low, medium or high) for 14 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cariprazine 3 mg | |
| DRUG | Cariprazine 6 mg | |
| DRUG | Cariprazine 12.5 mg |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2009-03-17
- Last updated
- 2026-01-05
- Results posted
- 2021-04-12
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00862992. Inclusion in this directory is not an endorsement.